What Is Celecoxib 200 mg Used For? Conditions & Risks

Celecoxib 200 mg is a prescription anti-inflammatory drug used primarily to treat chronic pain and swelling from osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It belongs to a class of medications designed to reduce inflammation while sparing the stomach lining more than older painkillers do, though that stomach-friendliness comes with its own trade-offs in cardiovascular and kidney safety. The drug has also picked up uses in acute pain, menstrual cramps, and a rare hereditary condition that causes colon polyps, and researchers continue to explore whether it has a role in depression and cancer treatment.

How Celecoxib Works

Traditional anti-inflammatory drugs like ibuprofen and naproxen block two related enzymes in the body. One of those enzymes drives inflammation, pain, and fever. The other helps maintain the protective mucus lining of the stomach and supports normal kidney function and platelet activity. The problem with shutting down both at once is that you relieve the pain but also strip the stomach of its defenses, raising the risk of ulcers and bleeding.

Celecoxib was designed to block primarily the inflammation-driving enzyme while leaving the stomach-protective one largely alone. In theory, this selective approach would deliver the same pain relief with fewer gastrointestinal side effects.¹ That theory has largely held up in practice for the stomach, though the selectivity also affects the balance between blood vessel relaxation and clotting in ways that matter for heart health. Lab studies suggest celecoxib is somewhat less selective than rofecoxib (the drug pulled from the market in 2004), which may partly explain its comparatively better cardiovascular track record.²

Approved Uses in Arthritis

The bread-and-butter indication for celecoxib 200 mg is osteoarthritis, the wear-and-tear joint disease that affects tens of millions of people. A systematic review of randomized trials found that celecoxib matched traditional anti-inflammatory drugs on every measure of pain relief and physical function in osteoarthritis, while producing significantly fewer stomach problems.³ A large international trial confirmed those findings: both celecoxib 100 mg twice daily and 200 mg twice daily performed as well as naproxen or diclofenac for osteoarthritis pain, but the celecoxib group had roughly seven times fewer ulcer complications.⁴

In rheumatoid arthritis, celecoxib shows clear benefit over placebo. A Cochrane review found that people taking celecoxib were roughly 50% more likely to achieve meaningful clinical improvement than those on placebo, and they reported less pain.⁵ That review noted, however, that results for physical function were less clear-cut. Celecoxib is not a disease-modifying drug; it controls symptoms rather than slowing joint destruction, so it is typically used alongside other rheumatoid arthritis treatments.

Ankylosing Spondylitis

Ankylosing spondylitis is an inflammatory condition that mainly targets the spine and sacroiliac joints, causing chronic back pain and stiffness. Anti-inflammatory drugs are a first-line treatment, and celecoxib has earned its place among them. A 12-week Norwegian trial showed that both celecoxib 200 mg and 400 mg daily reduced pain and disease activity scores just as well as diclofenac, a widely used older anti-inflammatory.⁶ A separate trial in Chinese patients confirmed that celecoxib 200 mg once daily was non-inferior to sustained-release diclofenac for pain relief, disease activity, and physical function.⁷ Because people with ankylosing spondylitis often need daily anti-inflammatory treatment for years, the lower rate of stomach complications with celecoxib is a real advantage.

Acute Pain and Menstrual Cramps

Beyond chronic joint disease, celecoxib is approved for short-term acute pain and primary dysmenorrhea (painful periods). A Cochrane review of postoperative pain trials found that a single 200 mg dose gave at least 50% pain relief to about one in three people, meaning for roughly every four patients treated, one got meaningful relief who would not have with a sugar pill. Doubling the dose to 400 mg pushed that figure higher, with about 44% of patients achieving at least half their pain gone.⁸ An earlier Cochrane analysis compared the effect to familiar over-the-counter options and found single-dose celecoxib roughly similar in efficacy to aspirin 600 mg or acetaminophen 1000 mg.⁹

For menstrual cramps, two identically designed crossover studies in women aged 18 to 44 found that celecoxib (a 400 mg loading dose followed by 200 mg every 12 hours) outperformed placebo on every pain score and provided relief within an hour. Naproxen sodium performed similarly, and both drugs were well tolerated.¹⁰ In practice, celecoxib is most useful for menstrual pain when someone cannot tolerate standard anti-inflammatories because of stomach issues.

Familial Adenomatous Polyposis

One of the more surprising approved uses for celecoxib is in familial adenomatous polyposis, a hereditary condition in which hundreds to thousands of polyps develop in the colon, virtually guaranteeing colorectal cancer if left unchecked. Because the inflammation-driving enzyme celecoxib targets is overexpressed in many colon polyps, researchers tested whether blocking it could shrink them. A landmark trial published in the New England Journal of Medicine found that celecoxib 400 mg twice daily reduced the average number of colorectal polyps by about 28% and shrank the total polyp burden by about 31% over six months, compared with negligible changes in the placebo group.¹¹

This benefit extends to children with the condition. A trial in pediatric patients showed that the highest dose of celecoxib reduced polyp counts by about 44% at three months, while the placebo group actually saw a 39% increase.¹² Celecoxib does not replace surgery for these patients; it is used as an adjunct to slow polyp growth, particularly in people who still have their colons or who have had subtotal colectomy.

The Stomach Advantage in Numbers

The central selling point of celecoxib has always been gentler treatment of the gut, and a recent systematic review and meta-analysis confirmed this with a broad look across anti-inflammatory drugs. Celecoxib carried the lowest risk of gastrointestinal bleeding of any drug analyzed, with an odds ratio barely above 1 and not statistically significant. For comparison, ibuprofen had roughly double the bleeding risk, and ketorolac (an injectable anti-inflammatory used mostly in hospitals) showed a dramatically higher risk.¹³

The GI advantage is especially relevant for people who need both an anti-inflammatory and aspirin for heart protection. A trial in high-risk patients who had already experienced upper gastrointestinal bleeding found that celecoxib combined with a proton pump inhibitor (a stomach acid-blocking drug) cut the 18-month risk of recurrent bleeding to about 6%, compared with roughly 12% for naproxen combined with the same stomach protector. The investigators concluded that naproxen should be avoided in these high-risk patients despite its perceived cardiovascular safety.¹⁴

Cardiovascular Safety

After rofecoxib was withdrawn for increasing heart attack risk, celecoxib lived under a cloud of suspicion. The largest trial designed to settle the question, called PRECISION, randomized over 24,000 arthritis patients to celecoxib, ibuprofen, or naproxen and followed them for a mean of about 34 months. The primary cardiovascular outcome (a composite of heart attack, stroke, or cardiovascular death) occurred in about 2.3% of the celecoxib group, 2.5% of the naproxen group, and 2.7% of the ibuprofen group. Celecoxib was non-inferior to both comparators.¹⁵ A separate analysis from the same trial that included kidney endpoints found celecoxib carried significantly lower cardiorenal risk than ibuprofen.¹⁶

Another large trial called SCOT found similar cardiovascular event rates between celecoxib and traditional anti-inflammatory drugs in routine clinical practice.¹⁷ Taken together, the evidence suggests celecoxib at standard doses does not carry measurably higher cardiovascular risk than ibuprofen or naproxen. That said, people with established heart disease should use any anti-inflammatory drug cautiously, because the entire class nudges risk upward compared with using none at all.

An analysis of aspirin’s effect on the safety picture found that celecoxib has its most favorable overall safety profile when taken without aspirin. Adding aspirin narrows the gap between celecoxib and its competitors, though celecoxib still holds an edge on gastrointestinal and kidney events even with aspirin on board.¹⁸

Kidney Effects and Blood Pressure

All anti-inflammatory drugs can affect the kidneys, and celecoxib is no exception. A systematic review and meta-analysis found that celecoxib increases the risk of renal or blood pressure-related events compared with placebo by roughly 24 to 52%, depending on the outcome measured. These events include fluid retention, edema, blood pressure elevation, and reduced kidney function.¹⁹ In pooled clinical trial data, the most common kidney-related side effects were peripheral edema (swelling, seen in about 2% of patients), high blood pressure (under 1%), and worsening of existing high blood pressure (under 1%).²⁰

How does celecoxib compare head-to-head? A large trial found that celecoxib at supratherapeutic doses produced blood pressure spikes less often than either ibuprofen or diclofenac at standard doses. Among patients who started the trial with mildly reduced kidney function, only about 4% on celecoxib had clinically meaningful declines in kidney function, versus about 7% on either comparator.²¹ If you already have kidney disease or take medications that stress the kidneys, your doctor will want to monitor kidney function more closely while you are on celecoxib.

The Sulfonamide Allergy Question

Celecoxib’s prescribing label warns against use in people allergic to sulfonamides, and this creates confusion because sulfonamide antibiotics (like sulfamethoxazole) are a common allergy. Celecoxib does contain a sulfonamide chemical group, but its molecular structure differs from sulfonamide antibiotics in ways that matter for allergic reactions. The antibiotics contain a specific structural feature that triggers the most serious immune reactions, like skin blistering and hypersensitivity syndrome. Celecoxib lacks that feature entirely.²²

A pilot study tested celecoxib in six patients with documented sulfonamide antibiotic allergies. All six tolerated it without incident, supporting the idea that cross-reactivity between the two types of sulfonamide compounds is low.²³ That is a tiny study, so caution is still warranted, and many prescribers follow the label’s recommendation. But if you have been told you cannot take celecoxib solely because of a “sulfa allergy,” it is worth discussing the specifics of your reaction with your doctor rather than assuming the door is closed.

Drug Interactions Worth Knowing

The interaction that gets the most clinical attention is with warfarin, a widely used blood thinner. Case reports and FDA warnings indicate that celecoxib can boost warfarin’s anticoagulant effect, raising the risk of dangerous bleeding. In one documented case, the clotting measure used to monitor warfarin rose significantly five weeks after celecoxib was added. Anyone on warfarin should have their clotting levels checked more frequently when starting or stopping celecoxib.²⁴

Celecoxib is metabolized in the liver by an enzyme called CYP2C9. Drugs that inhibit or compete for this enzyme (including fluconazole, an antifungal, and certain other anti-inflammatories) can increase celecoxib blood levels. People who carry certain genetic variants of CYP2C9 metabolize celecoxib more slowly than average, which effectively means a standard dose produces a higher-than-expected drug level. If you metabolize the drug slowly and no one accounts for it, you may be more prone to side effects at the usual dose. This is one of the reasons celecoxib dosing sometimes starts at 100 mg rather than 200 mg, depending on the patient.

Pregnancy and Celecoxib

Anti-inflammatory drugs as a class are generally avoided in late pregnancy because they can cause premature closure of a key blood vessel in the fetus. A small pilot series examined celecoxib use during the second trimester for preterm labor and found that blood flow velocity in that fetal vessel did not change significantly during treatment, though it exceeded the normal range temporarily in three cases and returned to normal after the dose was reduced or stopped. The researchers suggested celecoxib might be tolerable for short courses in the second trimester under close ultrasound monitoring.²⁵ This remains a niche use, and standard guidance is to avoid all anti-inflammatory drugs after about 20 weeks of pregnancy unless there is a specific clinical reason and close fetal monitoring.

Celecoxib as an Add-On for Depression

An intriguing line of research explores whether celecoxib can boost the effect of antidepressant medications. The rationale is that low-grade inflammation appears to play a role in some cases of depression, and tamping it down might help antidepressants work better. A meta-analysis of randomized trials found a large effect when celecoxib 400 mg daily was added to standard antidepressant therapy for major depression, with substantially improved symptom scores and higher rates of remission and response compared with antidepressant-plus-placebo.²⁶ A more recent meta-analysis confirmed these findings, including preliminary evidence of benefit in mania.²⁷

The picture is not entirely rosy, though. A trial that added celecoxib to vortioxetine (a newer antidepressant) in patients with treatment-resistant depression found no benefit on any outcome, including depressive symptoms, cognition, and daily functioning.²⁸ The discrepancy may reflect differences in patient populations: the positive trials generally enrolled people earlier in their depression course, while the negative trial focused on treatment-resistant cases. For now, celecoxib for depression remains experimental, and no psychiatric guidelines recommend it as a standard add-on.

Early Signals in Cancer Research

Because the enzyme celecoxib targets is overexpressed in many solid tumors, oncology researchers have tested whether adding celecoxib to standard cancer treatment improves outcomes. A systematic review and meta-analysis of randomized trials found that celecoxib combined with standard adjuvant therapy modestly improved overall survival and that adding it to pre-surgical (neoadjuvant) treatment increased tumor response rates by about 25%.²⁹ The most promising results have appeared in colon, breast, prostate, and head and neck cancers.³⁰ These are encouraging early-stage findings, not a reason to start taking celecoxib for cancer prevention. The doses used in some trials are higher than the standard arthritis dose, and the risk-benefit math changes substantially when you move from treating daily pain to preventing a disease you may never get.

Taking Celecoxib With or Without Food

A pharmacokinetic study found that eating a high-fat meal alongside celecoxib delays absorption but barely changes the total amount of drug your body sees (about an 11% increase in overall exposure, which is not considered clinically meaningful).³¹ The practical upshot is that you can take celecoxib with or without food. Some people find it easier on the stomach with a meal, and there is no pharmacological reason not to. The capsule form is the most common, and for people who cannot swallow capsules, the contents can sometimes be sprinkled on applesauce, though you should confirm this with your pharmacist because formulation-specific instructions vary.

Cost Considerations

Celecoxib went generic in 2014, which dropped the price considerably from its brand-name days. Still, it tends to cost more per pill than over-the-counter ibuprofen or naproxen. One way to think about the economics is that the higher drug cost may be offset by fewer gastrointestinal complications, which are expensive to treat. A cost-effectiveness study found that celecoxib, particularly when paired with a proton pump inhibitor, delivered more quality-adjusted life over six months than ibuprofen-plus-proton-pump-inhibitor regimens, and the cost difference fell well within standard thresholds for cost-effective care.³² Whether the math works the same way in every healthcare system depends on local drug pricing, but the principle holds: a slightly more expensive pill that prevents emergency room visits for GI bleeding can be the cheaper option overall.